CoChat

The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy

Open access
Ying, Hou-Qun, Chen, Jie, He, Bang-Shun, Pan, Yu-Qin, Wang, Feng, Deng, Qi-Wen, Sun, Hui-Ling, Liu, Xian, Wang, Shu-Kui · 2015 · Scientific Reports

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

A common deletion polymorphism within B-cell chronic lymphocytic leukemia-lymphoma like 11 gene (BIM) was deemed to be a genetic cause leading to compromised kinase inhibitor therapeutic efficacy in cancer individuals. However, the results reported were not consistent. Thus, a comprehensive meta-analysis containing 12 eligible studies including 1,532 Asian patients was conducted to investigate a steady and reliable conclusion. The results showed that BIM deletion polymorphism was significantly associated with tyrosine kinase inhibitor (TKI) clinical efficacy in term of response rate (Ph = 0.349, HR = 0.438, 95%CI = 0.274–0.699) and disease control rate (Ph = 0.941, HR = 0.370, 95%CI = 0.202–0.678) in EGFR-mutated NSCLC population, not in CML and HCC subgroups. Additionally, EGFR-mutated NSCLC patient harbored BIM deletion polymorphism was associated with a shorter progression-free survival (PFS) than those with BIM wild polymorphism (Ph = 0.580, adjusted HR = 2.194, 95%CI = 1.710–2.814). However, no significant association was examined between BIM deletion polymorphism and overall survival (OS) and toxic adverse events in EGFR-mutated NSCLC population and it was not associated with PFS and OS in HCC subgroup. These findings revealed that BIM deletion polymorphism might be a genetic cause of intrinsic resistance to TKI therapy and it could be emerged as an independent predictor to identify patients who would benefit from TKI targeted therapy in EGFR-mutated NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep11348

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of eligible study selection.
Figure 1 Flow chart of eligible study selection.CC BY · PubMed Central
Figure 2 The results of meta-analysis of association between BIM deletion polymorphism and response rate and disease control rate of kinase inhibitor therapy in malignancy. (A): BIM deletion polymorphism and response rate; (B): BIM deletion polymorphism and disease control rate.
Figure 2 The results of meta-analysis of association between BIM deletion polymorphism and response rate and disease control rate of kinase inhibitor therapy in malignancy. (A): BIM deletion polymorphism and response rate; (B): BIM deletion polymorphism and disease control rate.CC BY · PubMed Central
Figure 3 The results of meta-analysis of association between BIM deletion polymorphism and progression-free, overall survival in malignancy with kinase inhibitor therapy. (A) BIM deletion polymorphism and progression-free survival; (B) BIM deletion polymorphism and overall survival.
Figure 3 The results of meta-analysis of association between BIM deletion polymorphism and progression-free, overall survival in malignancy with kinase inhibitor therapy. (A) BIM deletion polymorphism and progression-free survival; (B) BIM deletion polymorphism and overall survival.CC BY · PubMed Central
Figure 4 Begg’s funnel plots of BIM deletion polymorphism and response rate, disease control rate and progression-free survival in malignancy with kinase inhibitor therapy. (A) BIM deletion polymorphism and response rate; (B) BIM deletion polymorphism and disease control rate; (C) BIM deletion polymorphism and progression-free survival.
Figure 4 Begg’s funnel plots of BIM deletion polymorphism and response rate, disease control rate and progression-free survival in malignancy with kinase inhibitor therapy. (A) BIM deletion polymorphism and response rate; (B) BIM deletion polymorphism and disease control rate; (C) BIM deletion polymorphism and progression-free survival.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 29

Metadata

Authors
Ying, H.-Q., Chen, J., He, B.-S., Pan, Y.-Q., Wang, F., Deng, Q.-W., Sun, H.-L., Liu, X., & Wang, S.-K.
Affiliations
  • Nanjing First Hospital (CN)
  • Nanjing Normal University (CN)
Venue
Scientific Reports
Published
2015-06-15
Volume
5
Issue
1
Pages
11348-11348
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2399332576
Cited by
29
References
49
Citations by year
2026: 3 · 2024: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 2 · 2015: 2
FWCI
0.83
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81172141)
  • Nanjing Medical Science and Technique Development Foundation (QRX11254, QRX11255)
  • Fundamental Research Funds for the Central Universities
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
BIM deletion polymorphism, BCL2L13, tyrosine kinase inhibitors, intrinsic drug resistance, EGFR-mutant non-small cell lung cancer, hepatocellular carcinoma, chronic myeloid leukemia, progression-free survival, predictive biomarkers, pharmacogenetics, targeted therapy
MeSH terms
Bcl-2-Like Protein 11, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Humans, Membrane Proteins, Neoplasms, Polymorphism, Genetic, Proto-Oncogene Proteins, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Gene Expression Regulation, Neoplastic, Survival Analysis, Treatment Outcome, Sequence Deletion, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Apoptosis Regulatory Proteins, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.